Limits...
Detection of pancreatic cancer biomarkers using mass spectrometry.

Kim K, Ahn S, Lim J, Yoo BC, Hwang JH, Jang W - Cancer Inform (2015)

Bottom Line: We performed preprocessing, and various classification methods with imputation were used to replace the missing values.By using various classification methods, we identified the commonly splitting protein peaks as m/z 1,465, 1,206, and 1,020.In the follow-up study, in which we assessed biomarkers in pancreatic cancer patients with diabetes after surgical resection, we found that the intensities of m/z at 1,465, 1,206, and 1,020 became comparable with those of diabetes-only patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Statistics, Seoul National University, Seoul, Republic of Korea.

ABSTRACT

Background: Pancreatic cancer is the fourth leading cause of cancer-related deaths. Therefore, in order to improve survival rates, the development of biomarkers for early diagnosis is crucial. Recently, diabetes has been associated with an increased risk of pancreatic cancer. The aims of this study were to search for novel serum biomarkers that could be used for early diagnosis of pancreatic cancer and to identify whether diabetes was a risk factor for this disease.

Methods: Blood samples were collected from 25 patients with diabetes (control) and 93 patients with pancreatic cancer (including 53 patients with diabetes), and analyzed using matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF/MS). We performed preprocessing, and various classification methods with imputation were used to replace the missing values. To validate the selection of biomarkers identified in pancreatic cancer patients, we measured biomarker intensity in pancreatic cancer patients with diabetes following surgical resection and compared our results with those from control (diabetes-only) patients.

Results: By using various classification methods, we identified the commonly splitting protein peaks as m/z 1,465, 1,206, and 1,020. In the follow-up study, in which we assessed biomarkers in pancreatic cancer patients with diabetes after surgical resection, we found that the intensities of m/z at 1,465, 1,206, and 1,020 became comparable with those of diabetes-only patients.

No MeSH data available.


Related in: MedlinePlus

ROC curves for each imputation methods with four classifiers.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4285963&req=5

f4-cin-suppl.7-2014-045: ROC curves for each imputation methods with four classifiers.

Mentions: In order to summarize the accuracy of each method, we present receiver operating characteristic (ROC) curves for each imputation method and for each of the four classifiers (Fig. 4). These ROC curves are based on 100 randomly split test and train sets.


Detection of pancreatic cancer biomarkers using mass spectrometry.

Kim K, Ahn S, Lim J, Yoo BC, Hwang JH, Jang W - Cancer Inform (2015)

ROC curves for each imputation methods with four classifiers.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4285963&req=5

f4-cin-suppl.7-2014-045: ROC curves for each imputation methods with four classifiers.
Mentions: In order to summarize the accuracy of each method, we present receiver operating characteristic (ROC) curves for each imputation method and for each of the four classifiers (Fig. 4). These ROC curves are based on 100 randomly split test and train sets.

Bottom Line: We performed preprocessing, and various classification methods with imputation were used to replace the missing values.By using various classification methods, we identified the commonly splitting protein peaks as m/z 1,465, 1,206, and 1,020.In the follow-up study, in which we assessed biomarkers in pancreatic cancer patients with diabetes after surgical resection, we found that the intensities of m/z at 1,465, 1,206, and 1,020 became comparable with those of diabetes-only patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Statistics, Seoul National University, Seoul, Republic of Korea.

ABSTRACT

Background: Pancreatic cancer is the fourth leading cause of cancer-related deaths. Therefore, in order to improve survival rates, the development of biomarkers for early diagnosis is crucial. Recently, diabetes has been associated with an increased risk of pancreatic cancer. The aims of this study were to search for novel serum biomarkers that could be used for early diagnosis of pancreatic cancer and to identify whether diabetes was a risk factor for this disease.

Methods: Blood samples were collected from 25 patients with diabetes (control) and 93 patients with pancreatic cancer (including 53 patients with diabetes), and analyzed using matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF/MS). We performed preprocessing, and various classification methods with imputation were used to replace the missing values. To validate the selection of biomarkers identified in pancreatic cancer patients, we measured biomarker intensity in pancreatic cancer patients with diabetes following surgical resection and compared our results with those from control (diabetes-only) patients.

Results: By using various classification methods, we identified the commonly splitting protein peaks as m/z 1,465, 1,206, and 1,020. In the follow-up study, in which we assessed biomarkers in pancreatic cancer patients with diabetes after surgical resection, we found that the intensities of m/z at 1,465, 1,206, and 1,020 became comparable with those of diabetes-only patients.

No MeSH data available.


Related in: MedlinePlus